Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), following the release of new prescription data from the commercial-stage specialty pharmaceutical company for its iron deficiency treatment Accrufer/Feraccru.
The key highlight from the analysis is the significant increase of 50% in prescriptions during the second quarter, specifically for Accrufer.
The number of doctors prescribing the drug for the first time has also shown a positive trend, with a considerable proportion of those doctors continuing to prescribe it in the following quarter.
Davison says that the company's efforts in commercialising the product are "going well", with more benefit expected to come following the expansion of their sales force in June.